{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T17:58:26Z","timestamp":1790186306541,"version":"4.1.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,1,29]],"date-time":"2022-01-29T00:00:00Z","timestamp":1643414400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,1,29]],"date-time":"2022-01-29T00:00:00Z","timestamp":1643414400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["U01-DA033336-05S1"],"award-info":[{"award-number":["U01-DA033336-05S1"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["K23DA042140-01A1"],"award-info":[{"award-number":["K23DA042140-01A1"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Addict Sci Clin Pract"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Extended-release buprenorphine (XRB) offers a novel approach to sustained monthly treatment for people who use opioids in criminal justice settings (CJS). This study explores the experiences of adults receiving XRB as a jail-to-community treatment.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods and findings<\/jats:title>\n                <jats:p>In-depth qualitative interviews were conducted among adult participants with opioid use disorder (OUD; n\u2009 =\u200916) who were recently released from NYC jails and maintained on XRB after switching from daily sublingual buprenorphine (SLB). Interviews elaborated on the acceptability and barriers and facilitators of XRB treatment pre- and post-release. Interviews were audio recorded, transcribed, and analyzed for content related to factors influencing XRB treatment uptake and community reentry. Important themes were grouped into systems, medication, and patient-level factors. Key systems-level factors influencing initiation of XRB in jail included an alternative to perceived stigmatization and privacy concerns associated with daily in-jail SLB administration and less concerns with buprenorphine diversion. In-jail peer networks positively influenced participant adoption of XRB. XRB satisfaction was attributed to reduced in-jail clinic and medication administration visits, perceived efficacy and blockade effects upon the use of heroin\/fentanyl following release, and averting the risk of criminal activities to fund opioid use. Barriers to retention included post-injection withdrawal symptoms and cravings attributed to perceived suboptimal medication dosing, injection site pain, and lack of in-jail provider information about the medication.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Participants were generally favorable to XRB initiation in jail and retention post-release. Further studies are needed to address factors influencing access to XRB in criminal justice settings, including stigma, ensuring patient privacy following initiation on XRB, and patient-, provider-, and correctional staff education pertaining to XRB.<\/jats:p>\n                <jats:p><jats:italic>Trial Registration<\/jats:italic> ClinicalTrials.gov Identified: NCT03604159.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13722-022-00288-4","type":"journal-article","created":{"date-parts":[[2022,1,29]],"date-time":"2022-01-29T12:03:03Z","timestamp":1643457783000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Perceptions and experiences toward extended-release buprenorphine among persons leaving jail with opioid use disorders before and during COVID-19: an in-depth qualitative study"],"prefix":"10.1186","volume":"17","author":[{"given":"Anna","family":"Cheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Badolato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Segoshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"McDonald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mia","family":"Malone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kumar","family":"Vasudevan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beita","family":"Badiei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison","family":"Sugarman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ross","family":"Macdonald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasdeep","family":"Mangat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Giftos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua D.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7393-7564","authenticated-orcid":false,"given":"Babak","family":"Tofighi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,1,29]]},"reference":[{"issue":"13","key":"288_CR1","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1056\/NEJMoa1505409","volume":"374","author":"JD Lee","year":"2016","unstructured":"Lee JD, Friedmann PD, Kinlock TW, et al. Extended-release naltrexone to prevent opioid relapse in criminal justice offenders. N Engl J Med. 2016;374(13):1232\u201342.","journal-title":"N Engl J Med"},{"key":"288_CR2","first-page":"1","volume":"28","author":"N Krawczyk","year":"2020","unstructured":"Krawczyk N, Mojtabai R, Stuart EA, Fingerhood MI, Agus D, Lyons BC, Weiner JP, Saloner B. Opioid agonist treatment is highly protective against overdose death among a US statewide population of justice-involved adults. Am J Drug Alcohol Abuse. 2020;28:1.","journal-title":"Am J Drug Alcohol Abuse"},{"issue":"3","key":"288_CR3","doi-asserted-by":"publisher","first-page":"e180558","DOI":"10.1001\/jamanetworkopen.2018.0558","volume":"1","author":"TNA Winkelman","year":"2018","unstructured":"Winkelman TNA, Chang VW, Binswanger IA. Health, polysubstance use, and criminal justice involvement among adults with varying levels of opioid use. JAMA Netw Open. 2018;1(3):e180558.","journal-title":"JAMA Netw Open"},{"key":"288_CR4","first-page":"27","volume":"7","author":"A Sharma","year":"2016","unstructured":"Sharma A, O\u2019Grady KE, Kelly SM, Gryczynski J, Mitchell SG, Schwartz RP. Pharmacotherapy for opioid dependence in jails and prisons: research review update and future directions. Subst Abuse Rehabil. 2016;7:27\u201340.","journal-title":"Subst Abuse Rehabil"},{"issue":"2","key":"288_CR5","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1080\/10826084.2017.1363238","volume":"53","author":"SE Wakeman","year":"2018","unstructured":"Wakeman SE, Rich JD. Barriers to medications for addiction treatment: how stigma kills. Subst Use Misuse. 2018;53(2):330\u20133.","journal-title":"Subst Use Misuse"},{"issue":"1","key":"288_CR6","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s13722-018-0124-2","volume":"13","author":"AM Bunting","year":"2018","unstructured":"Bunting AM, Oser CB, Staton M, Eddens KS, Knudsen H. Clinician identified barriers to treatment for individuals in Appalachia with opioid use disorder following release from prison: a social ecological approach. Addict Sci Clin Pract. 2018;13(1):23.","journal-title":"Addict Sci Clin Pract"},{"issue":"1","key":"288_CR7","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s13722-014-0023-0","volume":"10","author":"AD Fox","year":"2015","unstructured":"Fox AD, Maradiaga J, Weiss L, Sanchez J, Starrels JL, Cunningham CO. Release from incarceration, relapse to opioid use and the potential for buprenorphine maintenance treatment: a qualitative study of the perceptions of former inmates with opioid use disorder. Addict Sci Clin Pract. 2015;10(1):2.","journal-title":"Addict Sci Clin Pract"},{"key":"288_CR8","doi-asserted-by":"publisher","first-page":"108349","DOI":"10.1016\/j.jsat.2021.108349","volume":"127","author":"J Gryczynski","year":"2021","unstructured":"Gryczynski J, Lee JD, Dusek K, McDonald R, Sharma A, Malone M, Monico LB, Cheng A, DeVeaugh-Geiss A, Chilcoat HD. Use of non-prescribed buprenorphine in the criminal justice system: perspectives of individuals recently released from incarceration. J Subst Abuse Treat. 2021;127:108349.","journal-title":"J Subst Abuse Treat"},{"key":"288_CR9","doi-asserted-by":"publisher","first-page":"107837","DOI":"10.1016\/j.drugalcdep.2020.107837","volume":"208","author":"KE Smith","year":"2020","unstructured":"Smith KE, Tillson MD, Staton M, Winston EM. Characterization of diverted buprenorphine use among adults entering corrections-based drug treatment in Kentucky. Drug Alcohol Depend. 2020;208:107837.","journal-title":"Drug Alcohol Depend"},{"issue":"1\u20133","key":"288_CR10","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.drugalcdep.2008.08.006","volume":"99","author":"S Magura","year":"2009","unstructured":"Magura S, Lee JD, Hershberger J, Joseph H, Marsch L, Shropshire C, Rosenblum A. Buprenorphine and methadone maintenance in jail and post-release: a randomized clinical trial. Drug Alcohol Depend. 2009;99(1\u20133):222\u201330.","journal-title":"Drug Alcohol Depend"},{"issue":"1","key":"288_CR11","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1080\/08897077.2011.620475","volume":"33","author":"JD Lee","year":"2012","unstructured":"Lee JD, Grossman E, Truncali A, Rotrosen J, Rosenblum A, Magura S, Gourevitch MN. Buprenorphine-naloxone maintenance following release from jail. Subst Abus. 2012;33(1):40\u20137.","journal-title":"Subst Abus"},{"issue":"14","key":"288_CR12","doi-asserted-by":"publisher","first-page":"2409","DOI":"10.1080\/10826084.2019.1653324","volume":"54","author":"B Tofighi","year":"2019","unstructured":"Tofighi B, Williams AR, Chemi C, Suhail-Sindhu S, Dickson V, Lee JD. Patient barriers and facilitators to medications for opioid use disorder in primary care. Subst Use Misuse. 2019;54(14):2409\u201319.","journal-title":"Subst Use Misuse"},{"issue":"1","key":"288_CR13","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s13722-019-0166-0","volume":"14","author":"M Velasquez","year":"2019","unstructured":"Velasquez M, Flannery M, Badolato R, et al. Perceptions of extended-release naltrexone, methadone, and buprenorphine treatments following release from jail. Addict Sci Clin Pract. 2019;14(1):37.","journal-title":"Addict Sci Clin Pract"},{"issue":"4","key":"288_CR14","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.ijlp.2011.07.002","volume":"34","author":"IA Binswanger","year":"2011","unstructured":"Binswanger IA, Nowels C, Corsi KF, et al. \u201cFrom the prison door right to the sidewalk, everything went downhill,\u201d a qualitative study of the health experiences of recently released inmates. Int J Law Psychiatry. 2011;34(4):249\u201355.","journal-title":"Int J Law Psychiatry"},{"issue":"1","key":"288_CR15","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s12954-019-0296-4","volume":"16","author":"J Neale","year":"2019","unstructured":"Neale J, Tompkins CNE, Strang J. Prolonged-release opioid agonist therapy: qualitative study exploring patients\u2019 views of 1-week, 1-month, and 6-month buprenorphine formulations. Harm Reduct J. 2019;16(1):25.","journal-title":"Harm Reduct J"},{"key":"288_CR16","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.2147\/PPA.S180641","volume":"12","author":"M Gilman","year":"2018","unstructured":"Gilman M, Li L, Hudson K, et al. Current and future options for opioid use disorder: a survey assessing real-world opinion of service users on novel therapies including depot formulations of buprenorphine. Patient Prefer Adherence. 2018;12:2123\u20139.","journal-title":"Patient Prefer Adherence"},{"issue":"9","key":"288_CR17","doi-asserted-by":"publisher","first-page":"e2123032","DOI":"10.1001\/jamanetworkopen.2021.23032","volume":"4","author":"JD Lee","year":"2021","unstructured":"Lee JD, Malone M, McDonald R, Cheng A, Vasudevan K, Tofighi B, Garment A, Porter B, Goldfeld KS, Matteo M, Mangat J, Katyal M, Giftos J, MacDonald R. Comparison of treatment retention of adults with opioid addiction managed with extended-release buprenorphine vs daily sublingual buprenorphine-naloxone at time of release from jail. JAMA Netw Open. 2021;4(9):e2123032.","journal-title":"JAMA Netw Open"},{"key":"288_CR18","volume-title":"Designing and conducting mixed methods research","author":"JW Creswell","year":"2005","unstructured":"Creswell JW, Plano Clark VL. Designing and conducting mixed methods research. Thousand Oaks: SAGE Publications; 2005."},{"issue":"11","key":"288_CR19","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1111\/j.1360-0443.2005.01230.x","volume":"100","author":"J Neale","year":"2005","unstructured":"Neale J, Allen D, Coombes L. Qualitative research methods within the addictions. Addiction. 2005;100(11):1584\u201393.","journal-title":"Addiction"},{"key":"288_CR20","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.jsat.2019.06.007","volume":"104","author":"CNE Tompkins","year":"2019","unstructured":"Tompkins CNE, Neale J, Strang J. Opioid users\u2019 willingness to receive prolonged-release buprenorphine depot injections for opioid use disorder. J Subst Abuse Treat. 2019;104:64\u201371.","journal-title":"J Subst Abuse Treat"},{"issue":"2","key":"288_CR21","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1056\/NEJMsa064115","volume":"356","author":"IA Binswanger","year":"2007","unstructured":"Binswanger IA, Stern MF, Deyo RA, et al. Release from prison\u2014a high risk of death for former inmates. N Engl J Med. 2007;356(2):157\u201365.","journal-title":"N Engl J Med"},{"issue":"1","key":"288_CR22","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1177\/1078345816685311","volume":"23","author":"B Alex","year":"2017","unstructured":"Alex B, Weiss DB, Kaba F, Rosner Z, Lee D, Lim S, et al. Death after release: matching to improve care delivery. Corr Health Care. 2017;23(1):83\u20137.","journal-title":"Corr Health Care"},{"issue":"8","key":"288_CR23","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1111\/add.13803","volume":"112","author":"A Bukten","year":"2017","unstructured":"Bukten A, Stavseth MR, Skurtveit S, Tverdal A, Strang J, Clausen T. High risk of overdose death following release from prison: variations in mortality during a 15-year observation period. Addiction. 2017;112(8):1432\u20139.","journal-title":"Addiction"}],"container-title":["Addiction Science &amp; Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13722-022-00288-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13722-022-00288-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13722-022-00288-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,29]],"date-time":"2022-01-29T12:16:23Z","timestamp":1643458583000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpjournal.biomedcentral.com\/articles\/10.1186\/s13722-022-00288-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,29]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["288"],"URL":"https:\/\/doi.org\/10.1186\/s13722-022-00288-4","relation":{},"ISSN":["1940-0640"],"issn-type":[{"value":"1940-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,29]]},"assertion":[{"value":"12 August 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 January 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Institutional Review Board of the New York University Grossman School of Medicine and met criteria for allowable Federally funded research among prisoners per the Office of Human Research Protections.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"JDL has received in-kind study drugs from Indivior and Alkermes for other OUD clinical trials. JDL has received an Investigator Sponsored Study grant from Indivior for an unrelated study. JDL is a Science Advisor to Oar Health, an alcohol treatment product.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"4"}}